Skip to main content

Recent News & Research

Clinical Lung Cancer Logo
ResearchTreatments

Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective Phase I study

*December 2022* The treatment of LUAD-LM is particularly challenging and intrathecal pemetrexed is a potential therapeutic strategy for it, but still faces many obstacles caused by repeated lumbar puncture. We performed a prospective phase I study on 33 refractory LUAD-LM patients, aimed at assessing the safety, pharmacokinetic and clinical activity…
laurabbook@gmail.com
February 3, 2023
lungcancer.net
Coping With Cancer

Making the Most of Time Between Scans

*January 2023*  By EGFR Resisters Co-founder Ivy Elkins All of us living with lung cancer, whether diagnosed at an early stage or later stage, have to deal with periodic scans. Those of us with metastatic disease usually have scans every three months, while others with local disease might have them less…
laurabbook@gmail.com
February 3, 2023
lungevity
ResearchTreatments

Science Spotlight: NSCLC Transformation to SCLC

*December 2022* Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Dr. Triparna Sen as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC,…
laurabbook@gmail.com
December 19, 2022
targeted oncology
ResearchTreatments

Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification

*November 2022* The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of…
laurabbook@gmail.com
December 19, 2022
Onc Live
ResearchTreatments

HARMONIC Evaluates Novel Combination in Growing Population of Never Smokers With Advanced Lung Cancer

*November 2022* Never smokers represent a subgroup of patients with advanced lung cancer whose genetic makeup necessitates the need for targeted therapies and clinical trials aimed at improving outcomes. Compared with smokers, defined as those who smoke over 100 cigarettes in their life, never smokers have associated germline mutations for…
laurabbook@gmail.com
December 19, 2022